Laurus Labs Announces Q2 & H1 FY26 Results
Laurus Labs announces strong Q2 & H1 FY26 results with revenue growth of 35% and 33% respectively. EBITDA margins improved significantly. Interim dividend declared. Concall scheduled for October 23, 2025.
The strong financial results and growth indicate a positive outlook for the company, likely to have a significant impact on investor confidence and stock performance.
The announcement highlights strong financial performance with significant growth in revenue, EBITDA, and margins, along with the declaration of an interim dividend.
* Laurus Labs announced its Q2 & H1 FY26 results with strong growth in revenues and EBITDA. * Q2 FY26 revenues increased by 35% to ₹1,653 crore, and EBITDA grew by 136% to ₹429 crore with a margin of 26.0%. * H1 FY26 revenues increased by 33% to ₹3,223 crore, and EBITDA grew by 132% to ₹818 crore with a margin of 25.4%. * Gross margins improved by 4.5% to 59.6% due to favorable CDMO mix and operational improvements. * The company declared an interim dividend of ₹0.80 per share. * CDMO business reported H1 revenues of ₹1,040 crore, a 74% increase. * Generics business reported H1 revenues of ₹2,183 crore, a 20% increase. * R&D expenses for H1 FY26 were ₹137 crore (4.3% of revenues). * The company will hold an earnings conference call on October 23, 2025, at 5:00 p.m. IST.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.